Additional Required Payments For The Option To Acquire Business, Successful Development Milestones

No definition available.

Name:	rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones
Namespace Prefix:	rtrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Payments For The Option To Acquire Business

+ References

No definition available.

+ Details

Name:	rtrx_PaymentsForTheOptionToAcquireBusiness
Namespace Prefix:	rtrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount, after adjustment, of cost-method investment. Adjustments include, but are not limited to, dividends received in excess of earnings after date of investment that are considered a return of investment and other than temporary impairments.

+ References

No definition available.

+ Details

Name:	us-gaap_CostMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The charge against earnings to reduce the carrying value of an interest continued to be held by the transferor in a securitized financial instrument.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 325
-SubTopic 40
-Section 35
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121566103&loc=d3e44297-111616

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

+ Details

Name:	us-gaap_ImpairmentOfRetainedInterest
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_VariableInterestEntityLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=rtrx_CensaPharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=rtrx_CensaPharmaceuticalsIncEquityHoldersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

FUTURE ACQUISITION RIGHT AND JOINT DEVELOPMENT AGREEMENT (Details) - USD ($) $ in Thousands	1 Months Ended
	Aug. 31, 2019	Jan. 31, 2018	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2016
Variable Interest Entity [Line Items]
Business combination-related contingent consideration			$ 68,600	$ 70,900	$ 25,000
Investment			$ 15,000
Impairment of long-term investment	$ 15,000
Censa Pharmaceuticals Inc.
Variable Interest Entity [Line Items]
Payments for the option to acquire business		$ 10,000
Business combination-related contingent consideration		19,900
Censa Pharmaceuticals, Inc, Equity Holders
Variable Interest Entity [Line Items]
Additional required payments for the option to acquire business, successful development milestones		$ 5,000